174 related articles for article (PubMed ID: 17062838)
21. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.
Dobrez DG; Mathes A; Amdahl M; Marx SE; Melnick JZ; Sprague SM
Nephrol Dial Transplant; 2004 May; 19(5):1174-81. PubMed ID: 15004264
[TBL] [Abstract][Full Text] [Related]
22. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
[TBL] [Abstract][Full Text] [Related]
23. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
24. Clinical uses of 1-alpha-hydroxy-ergocalciferol.
Park J; Rhee CM; Lau WL; Kalantar-Zadeh K
Curr Vasc Pharmacol; 2014 Mar; 12(2):306-12. PubMed ID: 23713877
[TBL] [Abstract][Full Text] [Related]
25. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
26. Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol.
Kant KS; Gonzalez AR; Hariachar S; Bernardo M; Duggal A; Engstrand S; Hunter J; Plone M; Hertel J
J Ren Nutr; 2012 Jan; 22(1):34-40.e2. PubMed ID: 21652220
[TBL] [Abstract][Full Text] [Related]
27. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
Dyer CA
Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
[TBL] [Abstract][Full Text] [Related]
28. Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis.
Noertersheuser PA; Pradhan RS; Klein CE; Williams LA; Palaparthy R; Garimella TS; Lichtenberger O; Awni WM
J Clin Pharmacol; 2012 Aug; 52(8):1162-73. PubMed ID: 21940716
[TBL] [Abstract][Full Text] [Related]
29. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
[TBL] [Abstract][Full Text] [Related]
30. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
31. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient.
Sprague SM; Ho LT
Clin Nephrol; 2002 Aug; 58(2):155-60. PubMed ID: 12227689
[TBL] [Abstract][Full Text] [Related]
32. Management of secondary hyperparathyroidism.
Cunningham J
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S35-40. PubMed ID: 16109140
[TBL] [Abstract][Full Text] [Related]
33. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.
Frazão JM; Elangovan L; Maung HM; Chesney RW; Acchiardo SR; Bower JD; Kelley BJ; Rodriguez HJ; Norris KC; Robertson JA; Levine BS; Goodman WG; Gentile D; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2000 Sep; 36(3):550-61. PubMed ID: 10977787
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
Cheng J; Zhang W; Zhang X; Li X; Chen J
Clin J Am Soc Nephrol; 2012 Mar; 7(3):391-400. PubMed ID: 22223607
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
Joist HE; Ahya SN; Giles K; Norwood K; Slatopolsky E; Coyne DW
Clin Nephrol; 2006 May; 65(5):335-41. PubMed ID: 16724654
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of oral doxercalciferol (Hectorol) or paricalcitol (Zemplar) in the Cyp27b1-null mouse model of uremia.
St-Arnaud R; Arabian A; Akhouayri O; Knutson JC; Strugnell SA
Nephron Exp Nephrol; 2011; 119(3):e67-74. PubMed ID: 21849802
[TBL] [Abstract][Full Text] [Related]
37. [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience].
Pulvirenti D; Aikaterini T; Campagna A; Ignaccolo L; Giustolisi N; Costa E
Clin Ter; 2008; 159(5):307-10. PubMed ID: 18998031
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
[TBL] [Abstract][Full Text] [Related]
39. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
Mittman N; Desiraju B; Meyer KB; Chattopadhyay J; Avram MM
Kidney Int Suppl; 2010 Aug; (117):S33-6. PubMed ID: 20671742
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.
Moe SM; Saifullah A; LaClair RE; Usman SA; Yu Z
Clin J Am Soc Nephrol; 2010 Feb; 5(2):299-306. PubMed ID: 20056760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
